Liposomal Bupivacaine Use in Third Molar Impaction Surgery: INNOVATE Study
Study Overview
This study assessed the effectiveness and safety of liposomal bupivacaine (LB) for pain relief after third molar extraction. It was a phase 3, double-blind, placebo-controlled trial involving patients who underwent bilateral third molar extractions.
Study Design
Participants were randomly assigned to receive either LB (133 mg/10 mL) or a placebo. They could also take opioid pain relief if needed. The main measure of pain relief was the total pain score over 48 hours after surgery.
Results
In the main group of 150 participants, the average pain score for LB was 172.3, compared to 194.7 for the placebo (P = .227). In a more strictly followed group of 89 participants, LB had a lower pain score of 120.8 versus 183.3 for the placebo (P = .023). Significant differences in pain scores were noted in this stricter group, indicating LB was more effective.
Conclusion
The study shows that liposomal bupivacaine can significantly reduce pain after third molar surgery, but more research is needed due to some protocol violations in the trial.
Importance of Clinical Trials
Clinical trials are essential for creating safe and effective treatments. To help integrate these findings into everyday medical practice, we offer DocSym, an AI-driven platform that combines ICD-11 standards, clinical protocols, and research into one easy-to-use resource for healthcare providers.
Streamlining Healthcare
In today’s healthcare landscape, improving efficiency is vital. Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, simplifying patient care management and expanding digital services.
Enhancing Patient Outcomes
By leveraging AI, clinics can optimize workflows, improve patient outcomes, and reduce paperwork. Discover how we can support your practice at aidevmd.com.
